Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Rev Esp Quimioter ; 36(3): 259-266, 2023 Jun.
Article in Spanish | MEDLINE | ID: mdl-36966384

ABSTRACT

Mycoplasma pneumoniae is a bacterium that lacks a cell wall. It produces infections all It produces infections world-wide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique.


Subject(s)
Mycoplasma pneumoniae , Pneumonia, Mycoplasma , Humans , Mycoplasma pneumoniae/genetics , Macrolides/pharmacology , Macrolides/therapeutic use , Drug Resistance, Bacterial , Pneumonia, Mycoplasma/drug therapy , Pneumonia, Mycoplasma/epidemiology , Pneumonia, Mycoplasma/diagnosis , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Europe/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...